Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis

Autor: Díaz-Villamarín, Xando, Blánquez-Martínez, David, Pozo-Agundo, Ana, Pérez-Gutiérrez, Ana María, Muñoz-Ávila, José Ignacio, Antúnez-Rodríguez, Alba, Fernández-Gómez, Ana Estefanía, García-Navas, Paloma, Martínez-González, Luis Javier, Dávila-Fajardo, Cristina Lucía
Přispěvatelé: [Díaz-Villamarín,X, Fernández-Gómez,AE, García-Navas,P, Dávila-Fajardo,CL] Pharmacy Department, Hospital Universitario Clínico San Cecilio—Instituto de Investigación Biosanitaria (ibs.Granada), Granada, Spain. [Díaz-Villamarín,X, Pozo-Agundo,A, Antúnez-Rodríguez,A, Martínez-González,LJ] Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Granada, Spain. [Blánquez-Martínez,D] Pharmacy Department, Hospital Universitario de Ceuta, Ceuta, Spain. [Pérez-Gutiérrez,AM] Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, Granada, Spain. [Muñoz-Ávila,JI] Ophthalmology Department—Hospital Universitario Clínico San Cecilio, Granada, Spain.
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Chemicals and Drugs::Amino Acids
Peptides
and Proteins::Proteins::Intercellular Signaling Peptides and Proteins::Angiogenic Proteins::Vascular Endothelial Growth Factors::Vascular Endothelial Growth Factor A [Medical Subject Headings]
Diseases::Eye Diseases::Retinal Diseases::Retinal Degeneration [Medical Subject Headings]
genetic structures
Polimorfismo de nucleótido simple
Polypoidal choroidalvasculopathy
SNP
Polymorphism
Single Nucleotide
Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]
Neovascularización coroidal
Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Angiogenesis Inhibitors [Medical Subject Headings]
Medicina de precisión
Anti-VEGF
Farmacogenética
Chemicals and Drugs::Amino Acids
Peptides
and Proteins::Proteins [Medical Subject Headings]
High-Temperature Requirement A Serine Peptidase 1
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques
Ophthalmological::Fluorescein Angiography [Medical Subject Headings]
Personalized medicine
eye diseases
Diseases::Pathological Conditions
Signs and Symptoms::Pathologic Processes::Metaplasia::Neovascularization
Pathologic::Choroidal Neovascularization [Medical Subject Headings]
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques
Ophthalmological::Vision Tests::Visual Acuity [Medical Subject Headings]
Factor A de crecimiento endotelial vascular
Pharmacogenetics
sense organs
Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings]
Phenomena and Processes::Genetic Phenomena::Genetic Variation [Medical Subject Headings]
Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers
Pharmacological [Medical Subject Headings]
Diseases::Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular Degeneration::Wet Macular Degeneration [Medical Subject Headings]
Popis: Polypoidal choroidal vasculopathy (PCV) is usually regarded as a subtype of choroidal neovascularization (CNV) that is secondary to age-related macular degeneration (AMD) characterized by choroidal vessel branching, ending in polypoidal lesions. Despite their close association, PCV and neovascular AMD have shown differences, especially regarding patients' treatment response. Currently, antivascular endothelial growth factor (anti-VEGF) drugs, such as ranibizumab, bevacizumab and aflibercept, have demonstrated their efficacy in CNV patients. However, in PCV, anti-VEGF treatments have shown inconclusive results. Many genetic polymorphisms have been associated with a variable response in exudative/wet AMD patients. Thus, the aim of this study is to explore the genetic variants affecting anti-VEGF drug response in PCV patients. In this regard, we performed a systematic review and meta-analysis. We found four variants (CFH I62V, CFH Y402H, ARMS2 A69S, and HTRA1-62A/G) that have been significantly related to response. Among them, the ARMS2 A69S variant is assessed in our meta-analysis. In conclusion, in order to implement anti-VEGF pharmacogenetics in clinical routines, further studies should be performed, distinguishing physio-pathogenic circumstances between PCV and exudative AMD and the combined effect on treatment response of different genetic variants. Yes
Databáze: OpenAIRE
Externí odkaz: